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Background. Recent data support that iodixanol, an
iso-osmolality contrast agent, is less nephrotoxic than low-
osmolality contrast agents when hydration is the only prophy-
lactic strategy used. We evaluated the nephrotoxicity of iso- and
low-osmolality contrast agents with prophylactic administration
of N-acetylcysteine (NAC) along with hydration.
Methods. Two hundred and twenty-five patients with chronic
renal insufficiency (serum creatinine >1.5 mg/dL or an esti-
mated glomerular filtration rate <60 mL/min/1.73m2), referred
to our institution for coronary and/or peripheral procedures,
were assigned to receive low-osmolality (iobitridol group; N =
115) or iso-osmolality (iodixanol group; N = 110) contrast dye.
In all cases prophylactic administration of 0.45% saline intra-
venously and NAC (1200 mg orally twice daily) was used.
Results. Baseline creatinine levels were similar in the 2 groups
[iobitridol group = 1.70 (IQR: 1.54–1.98) mg/dL; iodixanol
group = 1.73 (IQR: 1.56–2.00) mg/dL, P = 0.33]. The risk score
for contrast nephrotoxicity was 5.0 ± 1.6 in the iobitridol group
versus 5.0 ± 1.8 in the iodixanol group (P = 0.44). Increase of
at least 0.5 mg/dL of the creatinine concentration 48 hours after
the procedure occurred in 4/115 patients (3.5%) in the iobitri-
dol group and 3/110 patients (2.7%) in the iodixanol group (P =
1.00; OR 0.78; 95% CI 0.17–3.56). Amount of contrast media
administration was similar in the 2 groups (iobitridol group =
167 ± 90 mL; iodixanol group = 164 ± 82 mL; P = 0.61).
Conclusion. Nephrotoxicity of iso-osmolality and low-
osmolality contrast agents was similar when a prophylactic strat-
egy of hydration plus NAC was utilized.
Radiocontrast media can lead to a reversible form of
acute renal failure that begins soon after the adminis-
tration of the dye and is generally benign [1]. However,
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transient dialysis may be required, especially in high-risk
patients [2–4]. The optimal strategy to prevent contrast
agent–associated nephrotoxicity (CAN) remains uncer-
tain. At present, recommendations are (1) periprocedu-
ral hydration [5], (2) use of a low-osmolality contrast
agent [6–8], and (3) limiting the amount of contrast agent
[9]. Recently, 2 additional strategies to be associated to
hydration aroused considerable interest: administration
of N-acetylcysteine (NAC) and the use of iso-osmolality
contrast agents. Several trials and meta-analysis support
the usefulness of oral NAC [10–15]. NAC is a potent an-
tioxidant compound that may prevent direct oxidative
tissue damage by scavenging reactive oxygen species [16,
17]. Iodixanol (an iso-osmolality contrast agent) seems to
be less nephrotoxic than low-osmolality contrast agents
[18]. It has therefore been suggested that, although more
expensive, use of iodixanol is cost-effective because the
extra cost may be offset by the reduced cost of managing
adverse reactions [19]. However, studies comparing iso-
versus low-osmolality contrast agents were conducted us-
ing hydration as the only prophylactic strategy to prevent
CAN. Therefore, it is unknown whether the difference
seen in the nephrotoxicity of low- and iso-osmolality con-
trast agents still exists when utilizing NAC plus hydration.
This data may have important clinical as well as economic
implications.
In order to clarify this issue, we performed a retrospec-
tive study of patients with chronic renal insufficiency who
have undergone coronary or peripheral procedures with
either low- or iso-osmolality contrast agents and were
concomitantly treated with NAC plus hydration. Patients
with diabetes mellitus were also analyzed separately.
METHODS
Patient population
This is a nonrandomized, observational study including
all consecutive patients with chronic renal insufficiency
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(serum creatinine concentration ≥1.5 mg/dL and/or or an
estimated glomerular filtration rate <60 mL/min/1.73m2)
[20] who had coronary and/or peripheral angiography
and/or angioplasty in our institutions from January 2002
to December 2003. Most of patients of the present study
have been previously reported [13, 14]. All patients
received intravenous saline plus NAC before and af-
ter administration of the contrast agent. Saline (0.45%)
was given intravenously at a rate of 1 mL/kg of body
weight per hour (0.5 mL/kg for patients with left ven-
tricular ejection fraction <40%) for 12 hours before and
12 hours after administration of the contrast agent [5].
NAC (Fluimucil; Zambon Group SpA, Milan, Italy) was
given orally at a dose of 1200 mg twice daily on the day
before and on the day of administration of the contrast
agent (total of 2 days) [13]. None of the patients re-
ceived theophylline, dopamine, mannitol, or furosemide
during the study. Serum creatinine, blood urea nitrogen,
sodium, and potassium were measured immediately be-
fore and 48 hours after administration of the contrast
agent; additional measurements were performed in all
cases of significant impairment of renal function. Esti-
mated glomerular filtration rate (eGFR) was calculated
by applying the Level modified Modification of Diet
in Renal Disease (MDRD) formula: (186.3 × serum
creatinine−1.154) × (age−0.203) × (0.742 if female) [20].
Proteinuria was determined by an immunometric as-
say (NycoCard® U-Albumin; Axus-Schiled PoCAS, Oslo,
Norway). Microalbuminuria and macroalbuminuria were
defined as protein excretion of 30 to 300 mg/24h and
>300 mg/24h, respectively. The risk score for predicting
CAN was calculated according to Mehran et al [21].
Contrast agents
Iobitridol (Xenetin-350, 350 mg iodine/mL; Guerbet,
France), a nonionic, low-osmolality (915 mOsm per kg
of water) contrast agent was administered to patients of
the iobitridol group. Iodixanol (Visipaque®, 320 mg io-
dine/mL; Amersham Health), a nonionic, iso-osmolality
(290 mOsm per kg of water) contrast agent was used in
the iodixanol group. Two different cutoffs were used to
define the high limit of contrast dye administered to each
enrolled patient: (1) ≥140 mL [14] and (2) (5 × kg body
weight) divided by serum creatinine (mg/dL): a weight-
and creatinine-adjusted maximum contrast dose (MCD)
[9]. This limit was converted to a dichotomous variable
by dividing the actual amount of contrast received by the
calculated MCD to determine the “contrast ratio.” If the
ratio was >1 then the MCD was defined as exceeded [9].
Follow-up
Acute contrast agent–associated nephrotoxicity was
defined as an increase in the serum creatinine concentra-
tion ≥0.5 mg/dL from the baseline value 48 hours, or the
need for dialysis after administration of the contrast me-
dia. Acute renal failure requiring dialysis was defined as a
decrease in renal function necessitating acute hemodial-
ysis, ultrafiltration, or peritoneal dialysis within the first
5 days’ postintervention.
The rates of early (<24 h) and late (>24 hours to
7 days) reactions to contrast agent were assessed [22].
Rate of major adverse events (death, acute myocardial in-
farction, stroke, new or repeated coronary or peripheral
revascularization and dialysis) at 12 months was assessed
in order to establish the long-term impact of contrast
nephropathy.
Statistical analysis
Continuous variables are given as mean ± 1 standard
deviation or median and interquartile ranges (IQR). Un-
paired Student t test was performed to determine dif-
ferences between mean values for continuous variables
when appropriate. Categorical variables were analyzed
by chi-square test. Creatinine and proteinuria concen-
trations were not normally distributed; therefore, the
nonparametric Wilcoxon and Mann-Whitney tests were
used to assess differences. To test the impact of con-
trast agent type (that is, iobitridol and iodixanol) on rate
of CAN, we used the 2 repeated measures analysis of
variance ANOVA and analysis of covariance ANCOVA
models after transforming creatinine levels into natural
logarithm (to overcome the problem of the non-normal
distribution). In the ANOVA model we considered the
treatment strategy (as defined in iobitridol group and
iodixanol group), time period, and time× treatment strat-
egy interaction as fixed effects and patients as a random
effect. In the ANCOVA model we put the log-creatinine
concentration at 48 hours as dependent variable, treat-
ment strategy (as defined in iobitridol and iodixanol
groups) as fixed factor, and baseline log-creatinine level
and the presence of diabetes mellitus as covariates. Prob-
ability values < 0.05 were considered significant. Data
were analyzed with SPSS 10.0 (Chicago, IL, USA) for
Windows.
RESULTS
Clinical characteristics
Two hundred and twenty-five patients were included in
the analysis. The clinical and biochemical characteristics
of the 225 patients in the 2 groups are shown in Tables 1
and 2. The total amount of intravenous hydration was
comparable: iobitridol group = 1798 ± 348 mL versus
iodixanol group = 1805 ± 283 mL (P = 0.99). The amount
of contrast agent administered was also similar in the 2
groups (iobitridol group: 167 ± 90 mL, iodixanol group
164 ± 82 mL; P = 0.61). A large volume (>140 mL) of
contrast dye was administered to 48% of iobitridol group
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Table 1. Clinical characteristics of the patients treated with
low-osmolality contrast agent (iobitridol group) and with
iso-osmolality contrast agent (iodixanol group)
Iobitridol Iodixanol
group group P
(N = 115) (N = 110) value
Age years 67 ± 10 67 ± 9 0.60
Male 98 (85%) 96 (87%) 0.70
Weight (kg) 76 ± 10 76 ± 13 0.85
Height (m) 1.67 ± 0.8 1.68 ± 0.7 0.82
Body mass index kg/m2 27 ± 3 26 ± 5 0.47
Blood pressure mm Hg
Systolic 138 ± 21 136 ± 19 0.57
Diastolic 76 ± 11 77 ± 11 0.62
Mean 97 ± 12 96 ± 12 0.55
Left ventricular ejection
fraction%
53 ± 12 51 ± 12 0.32
Systemic hypertension 89 (77.5%) 86 (79%) 0.87
Diabetes mellitus 49 (47%) 55 (51%) 0.23
Peripheral chronic artery
disease
32 (28%) 35 (32%) 0.56
Drugs
ACE inhibitor 72 (65.5%) 63 (57%) 0.21
Calcium channel blocker 52 (45%) 50 (45%) 0.85
Angiotensin II receptor
inhibitor
16 (14%) 16 (15%) 1.00
Diuretics 47 (41%) 52 (47%) 0.41
Performed procedure
Coronary angiography 58 (50%) 44 (40%) 1.14
PCI 15 (13%) 24 (22%) 0.11
Coronary angiography and
ad hoc PCI
32 (28%) 30 (27%) 1.00
Peripheral angiography 9 (8%) 6 (5.5%) 0.50
Peripheral angioplasty 1 (1%) 6 (5.5%) 0.06
Volume of contrast media mL 167 ± 90 164 ± 82 0.61
>140 mL 55 (48%) 63 (57%) 0.18
Contrast ratio >1 30 (26%) 34 (31%) 0.54
patients and 57.5% in the iodixanol group (P = 0.18). A
contrast ratio >1 occurred in 26% cases in the iobitridol
group and 31% cases in the iodixanol group (P = 0.54).
The incidence of early and late reactions to contrast agent
is reported in Table 3.
Contrast agent–associated nephrotoxicity
Serum creatinine concentration for all patients was 1.70
(IQR 1.55–1.99) mg/dL. In the iobitridol group, serum
creatinine concentration decreased from 1.70 (IQR 1.54–
1.98) mg/dL at baseline to 1.53 (IQR 1.35–1.85) mg/dL
48 hours after contrast agent administration (P < 0.001).
In the iodixanol group, serum creatinine concentration
decreased from 1.73 (IQR 1.56–2.00) to 1.66 (IQR 1.43–
1.90) mg/dL (P < 0.001). Contrast nephropathy risk score
was similar in the 2 groups. Most of the patients in the
2 groups had a risk score ≤5. None had a risk score ≥11
(Table 2). No interaction between contrast agent type
and creatinine level at 48 hours after procedure was ob-
served by the 2 repeat measure ANOVA (F = 2.27; P =
0.13) and even after including baseline creatinine level
and presence of diabetes mellitus as covariates (F = 1.20;
P = 0.27 by ANCOVA model). CAN (that is, increase
Table 2. Biochemical characteristics of the patients treated with
low-osmolality (iobitridol group) and iso-osmolality (iodixanol group)
contrast agents
Iobitridol Iodixanol
group group P
(N = 115) (N = 110) value
Serum creatinine, median (IQR) mg/dL
Baseline 1.70 (1.54–1.98) 1.73 (1.56–2.00) 0.33
After 48 hours 1.53 (1.35–1.85) 1.66 (1.43–1.90) 0.068
Serum creatinine >2.0
mg/dL
27 (23.5%) 27 (24.5%) 0.88
eGFR mL/min/1.73m2 40 ± 10 40 ± 9 0.69
40–60 66 (57%) 58 (53%)
20–40 46 (40%) 49 (44.5%)
<20 3 (3%) 3 (2.5%)
Contrast nephropathy
risk score
5.0 ± 1.6 5.0 ± 1.8 0.44
≤5 64% 60% 0.89
6–11 36% 38% 0.89
>11 0 0
Proteinuria, mg/24 h
(IQR)a
15 (0–45) 10 (0–67) 0.98
Serum urea nitrogen mg/dL
Baseline 67 ± 28 68 ± 25 0.89
After 48 hours 56 ± 23 60 ± 25 0.20
Serum sodium mEq/L
Baseline 141 ± 3 141 ± 3 0.30
After 48 hours 140 ± 8 141 ± 4 0.44
Serum potassium mEq/L
Baseline 4.9 ± 0.6 4.9 ± 0.6 0.85
After 48 hours 4.4 ± 0.6 4.5 ± 0.6 0.28
IQR, interquartile range; eGFR, estimated glomerular filtration rate.
a Proteinuria was available in 98 patients (85%) in the iobitridol group and 99
patients (90%) in the iodixanol group.
Table 3. Early (<24 hours) and late (>24 hours to 7 days) reactions
in patients treated with low-osmolality (iobitridol group) and
iso-osmolality (iodixanol group) contrast agents
Iobitridol Iodixanol
group group P
(N = 115) (N = 110) value
Early reactions 8 (7%) 6 (5.5%) 0.60
Urticaria 1 (0.9%) 1 (0.9%) 0.45
Nausea and/or vomiting 5 (4.3%) 5 (4.6%) 1.00
Pain 2 (1.8%) 0 0.45
Late reactions a 4 (3.7%) 9 (8.2%) 0.16
Skin rash a 3 (2.8%) 7 (6.3%) 0.20
Nausea 1 (0.9%) 1 (0.9%) 0.45
a Occurring for the first time after discharge and not a continuation of an early
skin reaction.
≥0.5 mg/dL of creatinine concentration) occurred in
4/115 patients of the iobitridol group (3.5%) and in 3/110
patients of the iodixanol group (2.7%) (P = 1.00; OR
0.58; 95% CI 0.17–3.56). No case of renal failure re-
quiring temporary dialysis occurred. In the 23 patients
with left ventricular ejection fraction <40%, renal func-
tion deterioration occurred in 1/11 (9%) in the iobitridol
group and none of the 12 patients in the iodixanol group
(P = 0.48). In patients given a large volume (>140 mL) of
contrast media (N = 116), CAN occurred in 2/55 (3.6%)
in the iobitridol group and in 1/61 (1.6%) in the iodixanol
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group (P = 0.60). Length of in-hospital stay (from admis-
sion to discharge) was similar in the 2 groups (iobitridol
group 2.2 ± 0.9 vs. iodixanol group 2.2 ± 0.6 days; P =
1.00).
At 1-year follow-up major adverse events occurred in
26 of the 115 (22.5%) patients in the iobitridol group and
in 33 of the 110 patients (30%) of the iodixanol group
(P = 0.22). Rate of death (8.7% vs. 11.8%, P = 0.66),
myocardial infarction (1.7% vs. 1.8%, P = 1.00), any
percutaneous or surgical coronary or peripheral revas-
cularization (10.5% vs. 14.5%, P = 0.42), and end-stage
renal failure requiring dialysis (2.6% vs. 3.6%, P = 0.71)
were similar in the 2 groups. Although not statistically sig-
nificant, occurrence of major adverse events was higher
in the 7 patients who experienced CAN (43% vs. 26%;
P = 0.38). Of note, end-stage renal failure requiring dial-
ysis at 12 months occurred in 2 of the 7 (28.5%) patients
who experienced CAN versus 5 of the 218 (2.3%) who
did not experienced CAN (P = 0.016; OR 17.1; 95% CI
2.65–110.4).
Diabetic patients
There were 104 diabetic patients, 49 in the iobitridol
group and 55 in the iodixanol group. Twenty-three pa-
tients (22%) were receiving insulin. The principal char-
acteristics of these patients were similar in the 2 groups
and are summarized in Table 4. In these patients, the risk
score for CAN was 5.5 ± 1.8 in the iobitridol group and
5.8 ± 1.8 in the iodixanol group (P = 0.40). Urinary pro-
tein excretion was similar in the 2 groups. In particular,
macroalbuminuria was observed in 12% of patients in the
iobitridol group and in 13% of the iodixanol group (P =
1.0). CAN occurred in 2/49 (4.1%) in iobitridol group and
in 3/55 (5.5%) in the iodixanol group (P = 1.00).
DISCUSSION
The main result of the present study is that the rate
of CAN in a low-to-medium risk population does not
seem to be different after the use of iobitridol or iodix-
anol when a prophylactic strategy of hydration plus NAC
administration is systematically used.
Low- versus iso-osmolality contrast agents
and nephrotoxicity
Experimental studies have provided conflicting data
regarding the role of osmolality in the pathogenesis of
CAN. Some studies indicated that the osmolality of the
contrast agent is a major determinant of CAN [23, 24],
whereas other studies demonstrated that the nephro-
toxic effect of contrast media is related to some property
other than osmolality [25]. Iodixanol is a dimeric non-
ionic contrast agent with lower osmolality and a higher
iodine ratio, but greater viscosity than most other com-
Table 4. Clinical characteristics of the patients with diabetes mellitus
treated with low-osmolality (iobitridol group) and iso-osmolality
(iodixanol group) contrast agents
Iobitridol Iodixanol
group group P
(N = 49) (N = 55) value
Age years 67 ± 8 68 ± 8 0.47
Insulin-requiring 10 (20.5%) 13 (23.5%) 0.81
Left ventricular ejection
fraction%
53 ± 10 50 ± 13 0.17
Serum creatinine, median (IQR) mg/dL
Baseline 1.68 (1.54–2.00) 1.79 (1.59–2.04) 0.61
After 48 hours 1.55 (1.40–1.91) 1.72 (1.48–2.03) 0.28
eGFR mL/min/1.73m2 39 ± 10 39 ± 9 0.94
40–60 24 (49%) 23 (42%)
20–40 24 (49%) 31 (56%)
<20 1 (2%) 1 (2%)
Proteinuria mg/24 h
(IQR)a
10 (0–47) 24 (0–200) 0.15
Microalbuminuria 11 (29%) 17 (36%) 0.51
Macroalbuminuria 5 (12%) 6 (13%) 1.00
Serum urea nitrogen mg/dL
Baseline 79 ± 31 70 ± 23 0.16
After 48 hours 66 ± 26 64 ± 23 0.77
Serum sodium mEq/L
Baseline 142 ± 3 141 ± 4 0.15
After 48 hours 142 ± 3 141 ± 4 0.12
Serum potassium mEq/L
Baseline 5.0 ± 0.7 5.0 ± 0.7 0.84
After 48 hours 4.6 ± 0.6 4.6 ± 0.7 0.71
Volume of contrast
media mL
176 ± 55 174 ± 80 0.43
>140 mL 24 (49%) 34 (62%) 0.17
Contrast ratio >1 14 (29%) 18 (33%) 0.67
IQR, interquartile range.
a Proteinuria was available in 41 patients (84%) in the iobitridol group and 47
patients (85%) in the iodixanol group
monly used contrast agents. The lower nephrotoxicity of
iodixanol versus low-osmolality contrast agents has been
substantiated by the following characteristics: (1) the di-
uretic effect of iodixanol is less than that of iomeprol and
ioxaglate, mostly due to the different osmolality [26]; and
(2) fractional of sodium excretion and urinary excretion
of N-acetyl-b-glucosaminidase and alkaline phosphatase
showed smaller increases with iodixanol than with iome-
prol and ioxaglate [27]. These findings may indicate that
iodixanol is less tubulotoxic than low-osmolality con-
trast agents. On the contrary, experimental studies in rats
showed that the higher viscosity of iodixanol (11.4 mPa
× sec at 37◦C vs. 10 mPa × sec of iobitridol) might
cause stasis in renal tubules, worsening medullary hy-
poxemia [28]. Although preliminary studies showed con-
flicting data on the lower nephrotoxic effect of iodixanol
compared to low-osmolality contrast agents [29–32], the
Nephrotoxic Effects in High-Risk Patients Undergoing
Angiography (NEPHRIC) trial [18] demonstrated that
iodixanol is less nephrotoxic than iohexol when adminis-
tered in patients with diabetes mellitus and chronic renal
insufficiency. Incidence of CAN was 26% (17/65) in the io-
hexol group versus 3% (2/64) in the iodixanol group (P =
0.002; OR 0.09; 95% CI 0.02–0.41). In the NEPHRIC trial
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hydration alone was used as a prophylactic strategy. In the
present study we found a very low incidence of CAN in
both groups and no significant difference in CAN rate
between iobitridol (3.5%) and iodixanol (2.7%) when a
systematic prophylactic strategy of hydration plus NAC
is utilized. Incidence of CAN in both groups is similar
to that observed in the iodixanol arm of the NEPHRIC
trial. Furthermore, in the subgroup of patients with dia-
betes mellitus, incidence of CAN was 4.1% in the iobitri-
dol group versus 5.5% in the iodixanol group. The 4.1%
rate of CAN observed in the iobitridol group is similar
to that observed in the iodixanol arm of the NEPHRIC
trial and very low compared to the iohexol arm (26%) of
the above trial and to what reported in the literature [1,
33].
Impact of NAC on nephrotoxicity
of low- and iso-osmolality contrast agents
The prophylactic administration of NAC along with hy-
dration may explain our different findings compared to
those reported in the NEPHRIC trial. NAC, a potent an-
tioxidant that scavenges a wide variety of oxygen-derived
free radicals, may prevent contrast-associated nephrotox-
icity by stopping direct oxidative tissue damage and also
by improving renal hemodynamics [16, 17, 34]. Following
the first observation by Tepel et al [10], a recent meta-
analysis evaluating over 800 high-risk patients enrolled
in randomized controlled trials supported that NAC plus
hydration significantly reduces the risk of CAN in pa-
tients with chronic renal insufficiency [15]. The antioxi-
dant effect of NAC seems to be dose-dependent. Indeed,
we recently demonstrated that a double-dose of NAC
(1200 mg/day for 2 days) seems to be more effective than
the standard dose [13]. NAC may prevent contrast agent
nephrotoxicity, equalizing differences in the chemical or
physical properties (besides osmolality) between iso- and
low-osmolality contrast agents.
Late reactions
The selection of contrast agent should take into ac-
count early and late reactions. The incidence of late reac-
tions ranges from 8% to 71% [22]. Although no contrast
agent is free from these side effects, late reactions have
been reported to be higher with iso-osmolality than low-
osmolality contrast agents [22]. Our study confirms this
previous finding of an excess number of late skin reac-
tions following the use of iodixanol. Although the course
of skin reactions appears benign, patients should be ad-
vised of this particular side effect, which may be difficult
to differentiate from that related to the use of other drugs,
such as clopidogrel.
Clinical implications
According to the results of the present study we can
state that, when a prophylactic strategy of hydration
plus NAC is utilized, the incidence of CAN in a low-to-
medium risk population does not seem to be significantly
influenced by the administration of whether an iso- or a
low-osmolality contrast agent. This result has important
clinical as well as economic implications. Contrast media
accounts for 10% of all causes of hospital-acquired renal
failure [1–4]. CAN causes a prolonged in-hospital stay
[13] and represents a powerful predictor of poor early
and late outcome [2–4]. Careful preprocedural stratifi-
cation has been recommended. The risk score proposed
by Mehran et al [21] is simple to calculate and very use-
ful for individual patient risk assessment. In the present
study, patients who experienced CAN had a 2-fold higher
risk of major adverse events and a 17-fold higher risk
of requiring dialysis at 1 year. Iodixanol is more expen-
sive than low-osmolality contrast agents. As recently sug-
gested, this increased cost may be offset by the reduced
cost of managing adverse reactions [19]. However, we did
not observe any significant difference in the rate of CAN
between the iodixanol and iobitridol groups. This result
was also confirmed in the subgroup of patients with dia-
betes mellitus. According to these data, and taking into
account the 2-fold higher risk of late dye-related reactions
observed in the iodixanol group, we do not recommend
the universal use of iodixanol to prevent CAN in the type
of patients included in our study, provided an optimal pro-
phylactic strategy of hydration plus NAC administration
is followed.
Study limitations
The retrospective nature of the study represents the
main limitation. The results of the present study cannot
be extended to patients at high or very high risk for CAN,
and all low-osmolality contrast agents.
CONCLUSION
The strategy of hydration plus NAC seems to elim-
inate any advantage of using the iso-osmolality versus
low-osmolality contrast agents in preventing CAN in a
low- to medium-risk population.
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